GlassScriptPhysician profile
Kevin E Macadaeg
NPI 1114011681
$337,204.34
in general payments reported to CMS, 2019-2025
12 companies · $6,365 in 2025
The $6,365 reported for 2025 was more than what 93% of Pain Medicine providers received nationally (typical 2025 total: $515).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $23K · 2020: $5,292 · 2021: $83K · 2022: $134K · 2023: $37K · 2024: $48K · 2025: $6,365.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $73K · Travel and Lodging: $8,281 · Consulting Fee: $6,270 · Food and Beverage: $4,226.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $72,750.00 |
| Travel and Lodging | $8,280.63 |
| Consulting Fee | $6,270.00 |
| Food and Beverage | $4,225.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Relievant Medsystems, INC. | $277,421.36 | 2019-2023 | Intracept |
| Boston Scientific Corporation | $46,740.44 | 2020-2025 | Intracept, General - Pain Management |
| Ferring Pharmaceuticals INC. | $7,615.49 | 2024-2025 | |
| Zimmer Biomet Holdings, INC. | $4,608.06 | 2019-2021 | |
| Vertos Medical, INC. | $376.78 | 2023-2024 | Mild Device Kit |
| Stryker Corporation | $167.55 | 2025 | Omnicurve |
| Medtronic USA, INC. | $146.88 | 2020 | |
| Nevro Corp. | $47.73 | 2024 | Senza |
| Painteq LLC | $38.36 | 2023 | Painteq |
| Saluda Medical Americas, INC. | $27.90 | 2025 | Evoke |
| Medtronic, INC. | $13.79 | 2024 | Intellis Adaptivestim |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kevin Macadaeg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.